8,090 Abbott Laboratories $ABT Shares Bought by Mirador Capital Partners LP

Mirador Capital Partners LP grew its holdings in Abbott Laboratories (NYSE:ABT) by 81.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 18,055 shares of the healthcare product maker’s stock after acquiring an additional 8,090 shares during the quarter. Mirador Capital Partners LP’s holdings in Abbott Laboratories were worth $1,784,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after acquiring an additional 6,769,518 shares in the last quarter. State Street Corp increased its stake in Abbott Laboratories by 1.7% in the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after buying an additional 1,350,766 shares during the period. J. Stern & Co. LLP lifted its stake in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Abbott Laboratories by 0.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,887,109 shares of the healthcare product maker’s stock worth $2,241,076,000 after acquiring an additional 118,014 shares during the period. Finally, Bank of America Corp DE purchased a new position in Abbott Laboratories during the second quarter worth about $1,603,607,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on ABT shares. Bank of America dropped their target price on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. JPMorgan Chase & Co. lifted their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Barclays assumed coverage on Abbott Laboratories in a report on Wednesday. They issued an “overweight” rating and a $120.00 target price for the company. Rothschild & Co Redburn raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and upped their price target for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Finally, BTIG Research raised their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $118.88.

Abbott Laboratories Stock Up 1.2%

Abbott Laboratories stock opened at $99.71 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $134.50. The firm has a market capitalization of $172.53 billion, a price-to-earnings ratio of 32.27, a price-to-earnings-growth ratio of 1.83 and a beta of 0.59. The stock’s fifty day moving average is $106.25 and its two-hundred day moving average is $98.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The business’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.